Zai Lab and Novocure Awarded Deal of the Year
November 14, 2018 07:30 ET
|
Zai Lab Limited
SHANGHAI, China, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NASDAQ: NVCR) today announced that...
Zai Lab Limited Announces Presentations at November Conferences
November 07, 2018 07:30 ET
|
Zai Lab Limited
SHANGHAI, China, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management team...
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
October 22, 2018 07:30 ET
|
Zai Lab Limited
ZEJULA is the first and only PARP inhibitor approved in Hong Kong for the maintenance treatment of platinum-sensitive relapsed ovarian cancer irrespective of BRCA mutation status Zai Lab expects to...
Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence
September 27, 2018 07:30 ET
|
Zai Lab Limited
Mr. Fu will oversee global business development, discovery, manufacturing and other operational activities in newly-created role Mr. Fu will lead expansion of U.S. operations and establish Zai Lab’s...
Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
September 26, 2018 07:30 ET
|
Zai Lab Limited
SHANGHAI, China, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, presented results of its open-label study to evaluate the...
Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
September 26, 2018 07:30 ET
|
Zai Lab Limited
Results demonstrate anti-tumor activity and manageable safety profile of the two dosing regimens of ZL-2301 tested in the trial Plan to pursue study to evaluate ZL-2301 in combination with anti-PD-1...
Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable
September 25, 2018 07:30 ET
|
Zai Lab Limited
SHANGHAI, China, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that senior management will participate in a...
Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China
September 12, 2018 16:20 ET
|
Zai Lab Limited
SHANGHAI, China, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, will host a conference call and webcast to discuss its...
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
September 05, 2018 20:59 ET
|
Zai Lab Limited
SHANGHAI, China, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced the pricing of...
Zai Lab Announces Proposed Public Offering of American Depositary Shares
September 02, 2018 19:30 ET
|
Zai Lab Limited
SHANGHAI, China, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it has...